# A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients

Study · id `cardio:ct-nct01225081` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01225081](<https://clinicaltrials.gov/study/NCT01225081>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01225081

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

## Technical summary

Registry record NCT01225081. Randomized; quadruple masking; primary purpose treatment. Start 2010-09-15 (actual); primary completion 2012-04-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 152 participants (enrolled count; ClinicalTrials.gov record NCT01225081, source copy `cardio:ctgov-nct01225081-2025-05-30`, retrieved 2026-10-26)
- Started: 2010-09-15 (actual) (ClinicalTrials.gov record NCT01225081, source copy `cardio:ctgov-nct01225081-2025-05-30`, retrieved 2026-10-26)
- Primary completion: 2012-04-28 (actual) (ClinicalTrials.gov record NCT01225081, source copy `cardio:ctgov-nct01225081-2025-05-30`, retrieved 2026-10-26)
- Completion: 2012-04-28 (actual) (ClinicalTrials.gov record NCT01225081, source copy `cardio:ctgov-nct01225081-2025-05-30`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01225081, source copy `cardio:ctgov-nct01225081-2025-05-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01225081-2025-05-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): ipragliflozin
- Intervention (Drug): Placebo
- Intervention (Drug): Pioglitazone
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: 0434b9af3622ad9021bb9e02be4e9ee755f2133ee478d16ae95d471be8bc0eaf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
